Trials / Completed
CompletedNCT01839604
A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma
A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I/Ib open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma.
Detailed description
A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients with Advanced/Metastatic Hepatocellular Carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD9150 | Intravenous infusion over 3 hours. |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2015-02-01
- Completion
- 2015-02-01
- First posted
- 2013-04-25
- Last updated
- 2017-03-06
- Results posted
- 2017-03-06
Locations
7 sites across 4 countries: Hong Kong, Japan, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT01839604. Inclusion in this directory is not an endorsement.